At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 351 enrolled
Drug / intervention
Nivolumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 2 other interventions for Prostate Cancer. Completed, enrolled 351 participants across 59 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesAustralia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMar 2017
Primary CompletionApr 2022
Study CompletionJan 2025
TodayJul 2026
First PostedDec 7, 2016
Enrollment StartMar 26, 2017
Primary CompletionApr 5, 2022
Study CompletionJan 7, 2025
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.6 years ago
Interventions
Nivolumabbiological
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days
Cabazitaxeldrug
Specified dose on specified days
Prednisonedrug
Specified dose on specified days